The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Open accessAbstract
Background—: Diastolic dysfunction in response to hypertrophy is a major clinical syndrome with few therapeutic options. MicroRNAs act as negative regulators of gene expression by inhibiting translation or promoting degradation of target mRNAs. Previously, we reported that genetic deletion of the cardiac-specific miR-208a prevents pathological cardiac remodeling and upregulation of Myh7 in response to pressure overload. Whether this miRNA might contribute to diastolic dysfunction or other forms of heart disease is currently unknown. Methods and Results—: Here, we show that systemic delivery of an antisense oligonucleotide induces potent and sustained silencing of miR-208a in the heart. Therapeutic inhibition of miR-208a by subcutaneous delivery of antimiR-208a during hypertension-induced heart failure in Dahl hypertensive rats dose-dependently prevents pathological myosin switching and cardiac remodeling while improving cardiac function, overall health, and survival. Transcriptional profiling indicates that antimiR-208a evokes prominent effects on cardiac gene expression; plasma analysis indicates significant changes in circulating levels of miRNAs on antimiR-208a treatment. Conclusions—: These studies indicate the potential of oligonucleotide-based therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Self-citationLNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 4×
“Single-stranded oligonucleotides have been shown to be effective in inactivating miRNAs in vivo 17–21 and represent a potentially effective means of inactivating pathological miRNAs.”
InfluentialTherapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Hill, J. A., & Olson, E. N. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072139 · Cited by 1,065
Self-citationA family of microRNAs encoded by myosin genes governs myosin expression and muscle performance
van Rooij, E., Quiat, D., Johnson, B. A., Sutherland, L. B., Qi, X., Richardson, J. A., Kelm, R. J., & Olson, E. N. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.10.013 · Cited by 960
Self-citationMicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice
Callis, T. E., Pandya, K., Seok, H. Y., Tang, R.-H., Tatsuguchi, M., Huang, Z.-P., Chen, J.-F., Deng, Z., Gunn, B., Shumate, J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36154 · Cited by 861
Hypertrophy of the Heart: A New Therapeutic Target?
Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000120390.68287.bb · Cited by 851
Self-citationCirculating microRNAs are new and sensitive biomarkers of myocardial infarction
D'Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P. G., Rubino, M., Carena, M. C., Spazzafumo, L., De Simone, M., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq167 · Cited by 797
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
MiR423-5p As a Circulating Biomarker for Heart Failure
Tijsen, A. J., Creemers, E. E., Moerland, P. D., de Windt, L. J., van der Wal, A. C., Kok, W. E., & Pinto, Y. M. (2010) · Circulation Research · doi:10.1161/circresaha.110.218297 · Cited by 664
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
LNA: a versatile tool for therapeutics and genomics
Petersen, M., & Wengel, J. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(02)00038-0 · Cited by 613
MicroRNAs Add a New Dimension to Cardiovascular Disease
Small, E. M., Frost, R. J. A., & Olson, E. N. (2010) · Circulation · doi:10.1161/circulationaha.109.889048 · Cited by 599
Self-citationMyosin heavy chain isoform expression in the failing and nonfailing human heart
Miyata, S., Minobe, W., Bristow, M. R., & Leinwand, L. A. (2000) · Circulation Research · doi:10.1161/01.res.86.4.386 · Cited by 538
Lowes, B. D., Minobe, W., Abraham, W. T., Rizeq, M. N., Bohlmeyer, T. J., Quaife, R. A., Roden, R. L., Dutcher, D. L., Robertson, A. D., Voelkel, N. F., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119770 · Cited by 503
Diversity of microRNAs in human and chimpanzee brain
Berezikov, E., Thuemmler, F., van Laake, L. W., Kondova, I., Bontrop, R., Cuppen, E., & Plasterk, R. H. A. (2006) · Nature Genetics · doi:10.1038/ng1914 · Cited by 502
Plasma miR-208 as a Biomarker of Myocardial Injury
Ji, X., Takahashi, R., Hiura, Y., Hirokawa, G., Fukushima, Y., & Iwai, N. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.125310 · Cited by 476
Specificity, duplex degradation and subcellular localization of antagomirs
Krützfeldt, J., Kuwajima, S., Braich, R., Rajeev, K. G., Pena, J., Tuschl, T., Manoharan, M., & Stoffel, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm024 · Cited by 455
MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases
Cortez, M. A., & Calin, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932889 · Cited by 436
Plasma MicroRNA 499 as a Biomarker of Acute Myocardial Infarction
Adachi, T., Nakanishi, M., Otsuka, Y., Nishimura, K., Hirokawa, G., Goto, Y., Nonogi, H., & Iwai, N. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.144121 · Cited by 383
van Rooij, E., Liu, N., & Olson, E. N. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.01.007 · Cited by 339
Self-citationAn abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy
Fatkin, D., McConnell, B. K., Mudd, J. O., Semsarian, C., Moskowitz, I. G. P., Schoen, F. J., Giewat, M., Seidman, C. E., & Seidman, J. G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11093 · Cited by 228
Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure
Gupta, M. P. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.07.045 · Cited by 223
Myocardial Gene Expression in Heart Failure Patients Treated With Cardiac Resynchronization Therapy
Vanderheyden, M., Mullens, W., Delrue, L., Goethals, M., de Bruyne, B., Wijns, W., Geelen, P., Verstreken, S., Wellens, F., & Bartunek, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.087 · Cited by 168
Microsomal triglyceride transfer protein expression during mouse development
Shelton, J. M., Lee, M., Richardson, J. A., & Patel, S. B. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32400-7 · Cited by 117
Patterns of myosin isoforms in mammalian skeletal muscle fibres
Hämäläinen, N., & Pette, D. (1995) · Microscopy Research and Technique · doi:10.1002/jemt.1070300505 · Cited by 105
Role of myosin heavy chain composition in the stretch activation response of rat myocardium
Stelzer, J. E., Brickson, S. L., Locher, M. R., & Moss, R. L. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.119719 · Cited by 61
microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Montgomery, R. L., & van Rooij, E. (2010) · Current Drug Targets · doi:10.2174/138945010791591368 · Cited by 33
Self-citation
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
MicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
Self-citationTherapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Metadata
- Authors
- Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N., & van Rooij, E.
- Venue
- Circulation
- Published
- 2011-10-04
- Volume
- 124
- Issue
- 14
- Pages
- 1537-1547
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2145244611
- Cited by
- 603
- References
- 30
- FWCI
- 34.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.